CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
|
|
- Myra Dennis
- 6 years ago
- Views:
Transcription
1 CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there is a dearth of culturally appropriate standardized measure to assess cognitive functions in early dementia. The main objectives of this study was to examine clinical validity of neuropsychological analysis for elderly in identifying early dementia and to evaluate the conversion rates to AD in subtypes of MCI and to identify neuropsychological measures most predictive of the time to conversion. Finally, we sought to identify which baseline neuropsychological measures from the comprehensive battery were the most predictive of time to AD conversion. The neuropsychological tests have been proved to be a useful marker for early diagnosis AD and discriminate the patients and controls. Most of the neuropsychological tests have been in regular use in the memory clinic at SCTIMST for more than 10 years. The proposed study is expected to identify neuropsychological analysis in the South Indian population that may serve as potential predictors of cognitive impairment or dementia in the elderly population in India. With the expected rise in the population at risk for dementia in the coming years in the country and the devastating nature of the disease for the patient as well as the family, ability to make early diagnosis or preclinical diagnosis will provide an enormous potential for disease modifying intervention, which is perhaps one of the most intensely researched areas that is making rapid progress internationally. 5.2 NEUROPSYCHOLOGICAL EVALUATION The neuropsychological test battery included measures of learning and memory, orientation abstract reasoning, language, attention, and visuospatial ability. Neuropsychiatric inventory test assesses 12 behavioral problems that commonly occur in people with dementias, including agitation, anxiety, apathy, delusions (fixed, false beliefs), hallucinations (sensing things that are not really there), euphoria (i.e.; extreme happiness or elation), dysphoria (i.e.; the opposite of euphoria), eating difficulties, loss of inhibition (the ability to hold back an extreme 57
2 emotion or behavior), irritability, irregular motor behavior (e.g.; shaking or trembling in just the hands or another body part), and sleeping disturbances [116]. All participants were invited to SCTIMST for the neuropsychological and neuroimaging tests on a mutually convenient appointment. All neuropsychological testing were carried out in the Neuropsychological testing rooms of the Cognition and Behavioural Neurology Section (CBNS) of the department of neurology. A qualified neurologist carried out all clinical assessments. All patients deemed requiring psychiatry consultation will be referred to the psychiatrist supporting the memory clinic at SCTIMST and as per the established procedure of this memory clinic. All neuropsychological evaluations will be carried out by a qualified, neuropsychology-trained and experienced psychologist who will be blinded to the clinical diagnosis of the subjects. All participants, after informed consent, will be subjected to clinical examination, which will consist of brief structured history for cognitive, and other neurological symptoms and risk factors and a detailed neurological examination at baseline, after 1 year (Visit-1) and after 2 years (Visit-2). They will also be subjected to a structured neuropsychological tests and radiological investigation at baseline, Visit-1 and Visit-2. When a subject receives a diagnostic categorization of DEM, he/she will transfer into the AD category. Clinical evaluation by a clinician using a brief structured standardized medical history examination and a bedside mental status examination. Qualified psychologists administered a battery of neuropsychological tests. Neuropsychological testing and interpretation of results in early diagnosis are more difficult. Each patient will undergo a brief cognitive screening battery Mini Mental State Examination (MMSE) and Addenbrooke's Cognitive Examination (ACE) to exclude undiagnosed cases of cognitive impairment. ACE assesses memory, concentration, and other cognitive skills [117][118]. The most frequently used mental status exam is called the Mini-Mental State Exam, a researchbased set of questions that results in a score representing a person's general level of cognitive functioning. The maximum score on the MMSE is 30. In general, scores of 24 or more are considered within the normal range of cognitive functioning; scores between 20 and 23 are suggestive of mild cognitive impairment or possible earlystage Alzheimer's disease scores between 10 and 19 are associated with middle-stage Alzheimer's; and a score of 9 or less is considered consistent with severe or late-stage 58
3 Alzheimer's disease. The MMSE is generally a reliable and valid indicator of cognitive impairment that can correctly distinguish between individuals with dementia, individuals with pseudo dementia due to depression, and individuals with depression and no cognitive impairment [119]. However, the test must be used with caution in certain groups of people. Another commonly used scale for evaluation of the staging severity of dementia is Clinical Dementia Rating (CDR) scale. It was developed primarily for use in persons with dementia of the Alzheimer type (the equivalent of probable AD) and it can also be used to stage dementia in other illnesses as well. It assesses six domains: memory, orientation, judgment and problem-solving, community affairs, home and hobbies and personal care [120]. The global CDR score is the weighted average of the category ratings. The ratings are 0 for healthy people, 0.5 for questionable dementia and 1, 2 and 3 for mild, moderate and severe dementia as defined in the CDR scale. The sum of boxes scores (CDRsb) are the sum of the category ratings [121]. 5.3 LONGITUDINAL AND CROSS-SECTIONAL ANALYSIS Demographic Clinical Features and Neuropsychological Performance Demographic details of the incident cohort are shown intable.3.1.the 49 MCI and 41 AD patients who presented with memory problems to a memory clinic at SCTIMST. Among the 23 MCI subjects participated in a longitudinal study of putative early markers of AD. Twenty three healthy control subjects, recruited were examined annually met the same inclusion/exclusion criteria and completed the same neuropsychological test battery. The institutional ethics committee reviewed and approved the research protocol, and written informed consent was obtained from each participant. The mean (SD) age of the incidence MCI cohort was (11.97) years and education was (3.96) at study entry. The 23 MCI subjects who completed cognitive testing on the ACE (79.82±11.02) and the MMSE (26.57±2.67) at baseline and (69±11.14) on the ACE and (25.5±1.98) on the MMSE at follow-up. The mean (SD) age of the incidence NCI cohort was (6.62) years and education was (4.19) at study entry. The 23 NCI subjects who completed cognitive testing on the ACE (93.87±4.74) and the MMSE (28.70±0.97) at baseline and (92.95±3.94) on the ACE and (28.02±0.87) and the MMSE at follow-up. The mean (SD) age of the incidence AD cohort was 69.88±09.08 years and education was 59
4 10.92 (3.92) at study entry. The 41 AD subjects who completed cognitive testing on the ACE (56.32±24.32) and the MMSE (17.68±6.93) at baseline Neuropsychological Prediction of Conversion to AD in Patients with MCI We investigated the earliest neuropsychological changes in Alzheimer s disease by comparing the baseline performance of 23 individuals who subsequently developed AD within an average of 2-3 years with 23 pair wise matched individuals who remained cognitively healthy (NCI). The patients with AD had significantly lower MMSE (p<0.000) and ACE scores (p<0.000) when compared to control subjects. Cognitive and functional ability screening were done at baseline and month follow-up assessments, among the 23 eligible participants who were mild cognitive impairment at baseline, 6 patients developed dementia after the 18 months follow-up duration and 17 patients were continue the stable state over a follow-up period average of 18 months. Participants with AD showed significantly poorer performance on every test including memory and non memory domains. However, tests of episodic and semantic memory were particularly sensitive in discriminating between normal and AD groups. At baseline, 49 MCI subjects aged greater than 55 years underwent cognitive and functional screening. Among the 49 subjects, 23 MCI subjects completed all of the incidence phase screening and evaluation procedures thus forming the incidence cohort. This longitudinal study included one subject, who had died after the first follow-up screening, the duration of follow-up of the incidence cohort ranged from 2 to 3 years. Both AD and MCI subjects were matched for age and gender. The mean education in the AD was and in MCI was When the neuropsychological performance of the two groups was compared it was seen that the AD performed significantly poorer than the MCI on 9 subcomponents in ACE and also on MMSE, RAVLT and Trail Making tests. On complex frontal executive tasks also the performance of AD was significantly impaired when compared to MCI [122]. Results indicate that on the ACE, MCI in comparison with NCI performed significantly poorer only in memory subtests. However AD on comparison to MCI showed impairment also on other cognitive sub tests too. On the MMSE, there was significant difference between MCI and NCI, whereas, AD patients scored significantly lower than MCI. On Semantic Battery, MCI showed significant 60
5 impairment in category fluency, while AD patients showed significant impairment in both category and letter fluency. On Trial making test, MCI was not seen to differ from NCI. Comparison of AD with MCI showed significantly more errors for AD in both Trail A and B. For Trail A, AD patients took more time to complete the task compared to MCI. Our results show that, neuropsychological the MCI when compared to NCI showed impairment only on tests involving memory but was comparable on all other cognitive tests. From our results we find that tests such as ACE, MMSE, SB and Trail making are able to pick up the transition from MCI to AD. Using Mann-Whitney tests we compared the performance of MMSE and ACE score on patients with controls. The MCI patients who converted to AD on follow-up evaluation with MCI patients who did not, hereafter referred to as MCI converters and MCI non converters or Progressive MCI and Stable MCI respectively. Using Mann-Whitney test we compared the performance of MCI and NCI at Visit 1 and also the difference between MCI at visit1 and AD. Results indicated in Table.5.1. Neuropsychological markers prove useful in the early identification of subjects at risk for conversion to dementia. Fig.5.1 shows the graphical representation of performance on MMSE and ACE across visit 1 and 2. Table.5.1. Longitudinal and discriminating study of MMSE and ACE NPI NCI MCI AD NCI vs MCI p value MCI vs AD NCI vs AD MMSE 28.70± ± ± ACE 93.87± ± ± Fig.5.1 demonstrates the graphical representation of MMSE and ACE score at baseline and follow-up data of MCI patients. The follow-up MMSE and ACE have decreased compared to baseline evaluation. 61
6 MMSE total ACE total visit 1 visit 2 Fig.5.1. Graphical representation of performance on MMSE and ACE across baseline and first follow-up. 5.4 DISCUSSION Using Mann-whitney test we compared the performance of MCI and NCI at Visit 1 and also the difference between MCI at visit1 (baseline) and MCI at visit 2. Results indicated in Table.5.1. This results indicates that at visit1 the MCI had significant impairment on MMSE (p<0.001) and ACE (p<0.000) tests of memory compared to NCI. In addition the NCI to AD was also significantly more than the NCI to MCI group. The mean education of AD was lower than MCI and NCI, while that of MCI and NCI were comparable. MCI and AD groups were comparable on age and NCI were younger. Results indicate that on the ACE, MCI on comparison with NCI performed significantly poorer only in memory subtests. However AD on comparison to MCI showed impairment also on other sub tests. Neuropsychology has contributed importantly to the characterization of the dementia associated with the neuropathology of AD, its differentiation from cognitive changes accompanying normal aging, and its distinction from dementias associated with other types of neuropathology. Obviously, diagnosing Alzheimer's is a complex process because the physician or team of health care professionals has a great deal of information to sort through. If a diagnosis of Alzheimer's is made, the next step is to then begin treating the disease and symptoms. As previously explained, there is no cure for AD. However, there are some treatments and approaches that can sometimes improve symptoms and/or quality of life. The first 62
7 stage of treatment is typically to address the person's cognitive symptoms with one or more of the medications described below. Although these drugs can be helpful, they cannot stop or reverse the disease, and eventually, the brain damage. The second stage of treatment is to address the person's environment or surroundings in order to maximize the person's functioning. The comparison of normal controls and AD groups indicated that normal controls consistently scored higher on neuropsychological tests. This indicates that neuropsychological battery can differentiate between the normal and clinical groups. The MCI converters were older and scored lower on the MMSE at baseline. During the 3-year follow-up, compared with MCI non-converters, converters had greater decline on MMSE scores. MCI converters scored lower than non-converters on all measures of verbal and nonverbal memory and executive function abilities. In this study, 6 MCI patients converted to AD during a mean follow-up of 18 months, remaining the 17 were classified at baseline and follow-up as stable MCI and one pure amnestic patient (amci) converted to AD on these follow up duration. 5.5 SUMMARY This chapter discusses and displays the analysis of different neuropsychological tests for the early diagnosis of AD and the longitudinal and cross sectional analysis result for discriminate the AD patients from controls. 63
NEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
More informationExploration of a weighed cognitive composite score for measuring decline in amnestic MCI
Exploration of a weighed cognitive composite score for measuring decline in amnestic MCI Sarah Monsell NACC biostatistician smonsell@uw.edu October 6, 2012 Background Neuropsychological batteries used
More informationNeuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia
86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile
More informationBehavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients
Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and
More informationOverview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why?
Neuropsychological assessment of older adults: what, when and why? Benjamin Mast, Ph.D. Associate Professor & Vice Chair, Psychological & Brain Sciences Associate Clinical Professor, Family & Geriatric
More informationNeuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
More informationDEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER
OVERCOMING THE CHALLENGES OF MANAGING CHRONIC DISEASES IN PERSONS WITH DEMENTIA DEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER LEARNING OBJECTIVES Be familiar with the diagnostic criteria for
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationAlzheimer s disease dementia: a neuropsychological approach
Alzheimer s disease dementia: a neuropsychological approach Dr. Roberta Biundo, PhD Neuropsychology Coordinator at Parkinson s disease and movement disorders unit of San Camillo rehabilitation hospital
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More informationRecent publications using the NACC Database. Lilah Besser
Recent publications using the NACC Database Lilah Besser Data requests and publications Using NACC data Number of requests by year Type 2009 2010 2011 2012 2013 2014 2015 Data files* 55 85 217 174 204
More informationMild cognitive impairment A view on grey areas of a grey area diagnosis
Mild cognitive impairment A view on grey areas of a grey area diagnosis Dr Sergi Costafreda Senior Lecturer Division of Psychiatry, UCL Islington Memory Service, C&I NHS FT s.costafreda@ucl.ac.uk London
More informationKingston Caregiver Stress Scale
Kingston Caregiver Stress Scale ADMINISTRATION AND INTERPRETATION MANUAL Seniors Mental Health Program, Providence Care Mental Health Services Kingston, Canada K7L 4X3 The Kingston Scales and Manuals can
More informationUDS version 3 Summary of major changes to UDS form packets
UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #283: Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationA Neuropsychiatric, Neuroradiological, and Neuropsychological Profile of a Cohort of Patients with Vascular Dementia
A Neuropsychiatric, Neuroradiological, and Neuropsychological Profile of a Cohort of Patients with Vascular Dementia Moises Gaviria, MD University of Illinois at Chicago Advocate Christ Medical Center
More informationService Related Project. Kimberley Keegan
AN EVALUATION OF ADDENBROOKE S COGNITIVE EXAMINATION III (ACE-III) SCORES, NEUROPSYCHOLOGICAL ASSESSMENT SCORES, AND DIAGNOSIS OUTCOME WITHIN A MEMORY SERVICE. Service Related Project Kimberley Keegan
More information02/04/2015. The structure of the talk. Dementia as a motor disorder. Movement, cognition & behaviour. Example 1. Example 2
The th Annual Memory Clinic Conference Dublin, Trinity College, 27 March 1 The structure of the talk Dementia as a motor disorder Thomas H. Bak Human Cognitive Neuroscience & Centre for Clinical Brain
More informationTHE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME
PERNECZKY 15/06/06 14:35 Page 1 THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME R. PERNECZKY, A. KURZ Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany. Correspondence
More informationPROJECTION: Worlds dementia population is expected to triple by 2050
DEMENTIA C L I S K C O N S U LTA N T P H Y S I C I A N I N A C U T E M E D I C I N E A N D G E R I AT R I C M E D I C I N E, B A R N E T H O S P I TA L, R O YA L F R E E N H S F O U N D AT I O N T R U
More informationCognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.
Cognitive Screening in Risk Assessment Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University Outline of Talk Definition of Dementia and MCI Incidence and Prevalence
More informationWhite matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration
White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration Annual Scientific Meeting Canadian Geriatric Society Philippe Desmarais,
More informationCapacity and Older Adults. Kenneth I. Shulman
Capacity and Older Adults Kenneth I. Shulman Increased Requests for Contemporaneous Assessments of Testamentary Capacity Increase in challenges to testamentary capacity Demographics/Economics Prevalence
More informationAnxiety, Depression, and Dementia/Alzheimer Disease: What are the Links?
The 2016 Annual Public Educational Forum Anxiety, Depression, and Dementia/Alzheimer Disease: What are the Links? Mary Ganguli MD MPH Professor of Psychiatry, Neurology, and Epidemiology, University of
More informationOutline. Minority Issues in Aging Research. The Role of Research in the Clinical Setting. Why Participate in Research
Outline Minority Issues in Aging Research Mary Sano, Ph.D Mount Sinai School of Medicine Bronx Veterans Medical Research Center 130 West Kingsbridge Rd Bronx NY, 10468 Phone: 718 741-4228; Fax: 718 562-9120
More informationORIGINAL ARTICLE Neuroscience INTRODUCTION MATERIALS AND METHODS
ORIGINAL ARTICLE Neuroscience DOI: 10.46/jkms.2010.25.7.1071 J Korean Med Sci 2010; 25: 1071-1076 Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring
More informationLambros Messinis PhD. Neuropsychology Section, Department of Neurology, University of Patras Medical School
Lambros Messinis PhD Neuropsychology Section, Department of Neurology, University of Patras Medical School Type 2 Diabetes Mellitus is a modern day epidemic Age is a significant predictor of diabetes Males
More informationTrail making test A 2,3. Memory Logical memory Story A delayed recall 4,5. Rey auditory verbal learning test (RAVLT) 2,6
NEUROLOGY/2016/790584 Table e-1: Neuropsychological test battery Cognitive domain Test Attention/processing speed Digit symbol-coding 1 Trail making test A 2,3 Memory Logical memory Story A delayed recall
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationIs Horticultural Therapy a Safe and Effective Treatment in Reducing Agitation for Dementia Patients in Nursing Homes?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2013 Is Horticultural Therapy a Safe and Effective
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationSpeech perception in individuals with dementia of the Alzheimer s type (DAT) Mitchell S. Sommers Department of Psychology Washington University
Speech perception in individuals with dementia of the Alzheimer s type (DAT) Mitchell S. Sommers Department of Psychology Washington University Overview Goals of studying speech perception in individuals
More informationAD Prevention Trials: An Industry Perspective
AD Prevention Trials: An Industry Perspective Robert A. Lasser, MD, MBA Global Development Lead, Product Development Group Medical Director, Neurodegenerative Disorders F. Hoffmann - La Roche Ltd Regulatory
More informationSECTION 1: as each other, or as me. THE BRAIN AND DEMENTIA. C. Boden *
I read all the available books by other [people with] Alzheimer s disease but they never had quite the same problems as each other, or as me. I t s not like other diseases, where there is a standard set
More informationAMNESTIC MINIMAL COGNITIVE IMPAIRMENT: BEYOND MEMORY
AMNESTIC MINIMAL COGNITIVE IMPAIRMENT: BEYOND MEMORY R. Balachandar 1,, R. Tripati 2, S. Bharath 1, S. Sadanand 1, P. T. Sivakumar 1, K. Kumar 2, S. Loganathan 1, S. R. Chandra 3, M. Vargese 1 1 Dept.
More informationDavid A Scott Lis Evered. Department of Anaesthesia and Acute Pain Medicine St Vincent s Hospital, Melbourne University of Melbourne
David A Scott Lis Evered Department of Anaesthesia and Acute Pain Medicine St Vincent s Hospital, Melbourne University of Melbourne This talk will include live polling so please be sure to have the meeting
More informationInformation Gathering Obtaining history is the most critical first step Patient-provided history may not be reliable Need info from relatives, friends
ASSESSING COMPETENCE Michael A Hill MD UNC Psychiatry 2008 Information Gathering Obtaining history is the most critical first step Patient-provided history may not be reliable Need info from relatives,
More informationAlzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT
Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms State of the art lecture March 4-2012 Philippe H Robert, Philippe Nice - France Robert The diagnosis of AD Neuropsychiatric
More informationWHOS complex needs clients data survey: assessment and treatment options
2 WHOS complex needs clients data survey: assessment and treatment options Assessment options: peer-reviewed and grey literature; policy, procedure and practice (PPP) 1: People With Exceptionally Complex
More informationScreening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia
Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral
More informationSOCIABLE - NEXT GENERATION COGNITIVE TRAINING USING MULTI-TOUCH SURFACE COMPUTERS
SOCIABLE - NEXT GENERATION COGNITIVE TRAINING USING MULTI-TOUCH SURFACE COMPUTERS Dr Paraskevi Sakka Neurologist - Psychiatrist Athens Association of Alzheimer s Disease and Related Disorders Neurodegenerative
More informationLANGUAGE IN INDIA Strength for Today and Bright Hope for Tomorrow Volume 8 : 2 February 2008
LANGUAGE IN INDIA Strength for Today and Bright Hope for Tomorrow Volume 8 : 2 February 2008 Managing Editor: M. S. Thirumalai, Ph.D. Editors: B. Mallikarjun, Ph.D. Sam Mohanlal, Ph.D. B. A. Sharada, Ph.D.
More informationLa cognizione sociale
15 Aprile 2015 - Firenze La cognizione sociale Chiara Cerami Divisione di Neuroscienze, Istituto Scientifico San Raffaele e Università Vita-Salute San Raffaele, Milano, Italy Theoretical Background Social
More informationPPMI Cognitive-Behavioral Working Group. Daniel Weintraub, MD
PPMI Cognitive-Behavioral Working Group Daniel Weintraub, MD PPMI Annual Meeting - May 6-7, 2014 Membership Daniel Weintraub WG Chair Tanya Simuni Steering Committee Shirley Lasch IND Chris Coffey, Chelsea
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationCan aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators
Can aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators ASPREE Randomized, double-blind, placebo-controlled trial for extending healthy
More informationAddressing Difficult Behaviors in Dementia
Addressing Difficult Behaviors in Dementia GEORGE SCHOEPHOERSTER, MD GERIATRICIAN GENEVIVE/CENTRACARE CLINIC Objectives By the end of the session, you will be able to: 1) Explain the role of pain management
More informationThe Basics of Alzheimer s Disease
2017 Memory Loss Conference The Basics of Alzheimer s Disease Tom Ala, MD Center for Alzheimer s Disease and Related Disorders Southern Illinois University School of Medicine Springfield, Illinois SIU
More informationCRITICALLY APPRAISED PAPER (CAP)
CRITICALLY APPRAISED PAPER (CAP) Godefroy, O., Fickl, A., Roussel, M., Auribault, C., Bugnicourt, J. M., Lamy, C., Petitnicolas, G. (2011). Is the Montreal cognitive assessment superior to the mini-mental
More informationThe place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
More informationThe role of memory on patients with mild cognitive impairment. Sophia Vardaki, PhD National Technical University of Athens
The role of memory on patients with mild cognitive impairment Sophia Vardaki, PhD National Technical University of Athens Athens, 26 June 2015 Objective-Presentation Structure Objective To explore the
More informationGERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
More informationKingston Caregiver Stress Scale
1 Kingston Caregiver Stress Scale ADMINISTRATION AND INTERPRETATION MANUAL The Kingston Scales and Manuals can be freely downloaded from: www.kingstonscales.org Caregiver Stress or email: kscales@queensu.ca
More informationWHI Memory Study (WHIMS) Investigator Data Release Data Preparation Guide April 2014
WHI Memory Study (WHIMS) Investigator Data Release Data Preparation Guide April 2014 1. Introduction This release consists of a single data set from the WHIMS Epidemiology of Cognitive Health Outcomes
More informationBurden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian
Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian German Center for Neurodegenerative Diseases (DZNE), site
More informationNon Alzheimer Dementias
Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,
More informationWhat APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias
What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias Presenter: Kim Bailey, MS Gerontology, Program & Education Specialist, Alzheimer s Orange County 1 1 Facts About Our
More informationKorean-VCI Harmonization Standardization- Neuropsychology Protocol (K-VCIHS-NP)
Korean-VCI Harmonization Standardization- Neuropsychology Protocol (K-VCIHS-NP) Yeonwook Kang, Ph.D. Department of Psychology, Hallym University Department of Neurology, Hallym University Sacred Heart
More informationParkinsonian Disorders with Dementia
Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University
More informationNeuropsychiatric Inventory Nursing Home Version (NPI-NH)
This is a Sample version of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) The full version of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) comes without sample watermark..
More informationIntra-Individual Reaction Time Variability in Mild Cognitive Impairment and Alzheimer s Disease: Gender, Processing Load and Speed Factors
Intra-Individual Reaction Time Variability in Mild Cognitive Impairment and Alzheimer s Disease: Gender, Processing Load and Speed Factors Michelle Phillips 1, Peter Rogers 2, Judy Haworth 3, Antony Bayer
More informationTable 2B: Summary of Select Screening and Initial Assessment Tools for Vascular Cognitive Impairment in Stroke Patients (Updated 2014)
Table 2B: Summary of Select Screening and Initial s for Vascular Cognitive Impairment in Stroke Patients (Updated 2014) Recommended First Line Screening and s Montreal Cognitive (MoCA) The MoCA is available
More informationCRASH COURSE IN OUTCOMES
CRASH COURSE IN OUTCOMES DR SUDIP SIKDAR FRCPSYCH, MD CONSULTANT OLD AGE PSYCHIATRIST ASSOCIATE MEDICAL DIRECTOR, OUTCOMES & PMH MERSEY CARE NHS FOUNDATION TRUST, LIVERPOOL Understanding the outcomes that
More informationWEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES
WEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES 1 CMS Medicare-Medicaid Coordination Office (MMCO) Established by Section 2602 of the Affordable Care Act Purpose:
More informationNumber of Items. Response Categories. Part V: Specific Behavior Scales-Sleep Scales. Based on past month
Part V: Specific Behavior Scales-Sleep Scales Based on past month First 4 items ask for time or amount of sleep 41. Pittsburgh Sleep Quality Index (PSQI) Sleep quality Sleep latency Sleep duration Habitual
More informationThe Quick Dementia Rating System (QDRS): A rapid dementia staging tool
Alzheimer s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 249-259 The Quick Dementia Rating System (QDRS): A rapid dementia staging tool James E. Galvin* Departments of Neurology, Psychiatry,
More informationUniversity of Groningen. Visual hallucinations in Parkinson's disease Meppelink, Anne Marthe
University of Groningen Visual hallucinations in Parkinson's disease Meppelink, Anne Marthe IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationSupplementary Online Content
Supplementary Online Content Devenney E, Bartley L, Hoon C, et al. Progression in behavioral variant frontotemporal dementia: a longitudinal study. JAMA Neurol. Published online October 26, 2015. doi:10.1001/jamaneurol.2015.2061.
More informationAlzheimer Disease and Related Dementias
Alzheimer Disease and Related Dementias Defining Generic Key Terms and Concepts Mild cognitive impairment: (MCI) is a state of progressive memory loss after the age of 50 that is beyond what would be expected
More informationNeuropsychological Testing (NPT)
Neuropsychological Testing (NPT) POLICY Psychological testing (96101-03) refers to a series of tests used to evaluate and treat an individual with emotional, psychiatric, neuropsychiatric, personality
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationPamela S. Klonoff, PhD Clinical Director Center for Transitional Neuro-Rehabilitation Barrow Neurological Institute, Phoenix, Arizona
Neuropsychology Pamela S. Klonoff, PhD Clinical Director Center for Transitional Neuro-Rehabilitation Barrow Neurological Institute, Phoenix, Arizona Top Ten Ways to Understand and Cope with a Brain Tumor
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationRange of neuropsychiatric disturbances in patients with Parkinson s disease
492 Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital D Aarsland N G Lim C Janvin Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway J P Larsen K Karlsen E Tandberg Departments
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationScreening for Cognitive Impairment
Screening for Cognitive Impairment Screening for Cognitive Impairment. Educational Consultant Pearson April 27, 2017 Presentation Title Arial Bold 7 pt 1 Agenda What is Cognitive Impairment? Implications
More informationQuality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment National Quality Strategy Domain: Effective Clinical Care
Quality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Cognitive impairment evaluated with Vascular Cognitive Impairment Harmonization Standards in a multicenter prospective stroke cohort in Korea Supplemental Methods Participants From
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationLearning objectives 6/20/2018
Cognitive impairment of patients with chronic migraine, in a neuropsychological assessment, does not depend on the use of topiramate or comorbidities Ferreira KS, MD, PhD Professor, Neurology Clinic, Medicine
More informationA Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies
A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies Lynda Mackin, PhD, AGPCNP-BC, CNS University of California San Francisco School of Nursing 1 Alzheimer s
More informationNIH Public Access Author Manuscript Dement Geriatr Cogn Disord. Author manuscript; available in PMC 2013 August 28.
NIH Public Access Author Manuscript Published in final edited form as: Dement Geriatr Cogn Disord. 2012 ; 34(2): 96 111. doi:10.1159/000342119. Neuropsychiatric symptoms and global functional impairment
More informationDementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician
Dementia Aetiology, pathophysiology and the role of neuropsychological testing Dr Sheng Ling Low Geriatrician Topics to cover Why is dementia important What is dementia Differentiate between dementia,
More informationMedicare Part C Medical Coverage Policy
Medicare Part C Medical Coverage Policy Neuropsychological Testing Origination: September 19, 2001 Review Date: February 21, 2018 Next Review: February, 2020 DESCRIPTION OF PROCEDURE SERVICE Neuropsychological
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #290: Parkinson s Disease: Psychiatric Symptoms Assessment for Patients with Parkinson s Disease National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationEARLY ONSET FRONTOTERMPORAL DEMENTIA AND ALZHEIMERS DISEASE: DIAGNOSIS, TREATMENT AND CARE
EARLY ONSET FRONTOTERMPORAL DEMENTIA AND ALZHEIMERS DISEASE: DIAGNOSIS, TREATMENT AND CARE John Rudge, BA Hons This thesis is presented as partial requirement for the degree of Doctor of Psychology at
More information22q11.2 Deletion Syndrome Fact Sheet - Treatable Psychiatric Illnesses in Adults
22q11.2 Deletion Syndrome Fact Sheet - Treatable Psychiatric Illnesses in Adults Anne S. Bassett (MD, FRCPC) Professor of Psychiatry, University of Toronto Director, Clinical Genetics Research Program,
More informationTest Assessment Description Ref. Global Deterioration Rating Scale Dementia severity Rating scale of dementia stages (2) (4) delayed recognition
Table S. Cognitive tests used in the Georgia Centenarian Study. Test Assessment Description Ref. Mini-Mental State Examination Global cognitive performance A brief screening of orientation, memory, executive
More informationI IADL. See Instrumental activities of daily living (IADL) Idiopathic rapid eye movement sleep behavior disorder (Idiopathic RBD), 136
A Abbreviated mental test (AMT) diagnostic performance, GPCOG, 205 screening instrument, 81 timescales, 214 ACE and revision (ACE-R). See also Addenbrooke s cognitive examination (ACE) clinical diagnosis,
More informationMeasuring health-related quality of life in persons with dementia DOMS results & recommendations
Measuring health-related quality of life in persons with dementia DOMS results & recommendations Madeleine King, Siggi Zapart, Jan Sansoni, Nick Marosszeky On behalf of the Dementia Outcomes Measurement
More informationClinical Differences Among Four Common Dementia Syndromes. a program of Morningside Ministries
Clinical Differences Among Four Common Dementia Syndromes a program of Morningside Ministries Introduction Four clinical dementia syndromes account for 90% of all cases after excluding reversible causes
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationThe Neuropsychiatric Inventory Questionnaire: Background and Administration
The Neuropsychiatric Inventory Questionnaire: Background and Administration The Neuropsychiatric Inventory Questionnaire (NPI-Q) was developed and crossvalidated with the standard NPI to provide a brief
More informationQUESTIONNAIRE: Finland
QUESTIONNAIRE: Finland To put the assessment and management of behavioural disorders into a broader context of social and health policy and services in Finland, some background information is presented.
More informationTable 7.2B: Summary of Select Screening Tools for Assessment of Vascular Cognitive Impairment in Stroke Patients
Table 7.2B: Summary of Select Screening Tools for Assessment of Vascular Cognitive Impairment in Stroke Patients Recommended First Line Screening and s Montreal Cognitive (MoCA) The MoCA is available for
More informationCRITICALLY APPRAISED PAPER (CAP)
CRITICALLY APPRAISED PAPER (CAP) FOCUSED QUESTION Is an individualized occupational therapy program more effective in modulating mood disturbances and functional deficits than general skills training for
More informationUniversity of Alberta
University of Alberta Longitudinal performance of Neuropsychological Assessments in Parkinson s Disease. by Taim Abdullah Muayqil A thesis submitted to the Faculty of Graduate Studies and Research in partial
More informationSession outline. Introduction to dementia Assessment of dementia Management of dementia Follow-up Review
Dementia 1 Session outline Introduction to dementia Assessment of dementia Management of dementia Follow-up Review 2 Activity 1: Person s story Present a person s story of what it feels like to live with
More informationDSM-5 MAJOR AND MILD NEUROCOGNITIVE DISORDERS (PAGE 602)
SUPPLEMENT 2 RELEVANT EXTRACTS FROM DSM-5 The following summarizes the neurocognitive disorders in DSM-5. For the complete DSM-5 see Diagnostic and Statistical Manualof Mental Disorders, 5th edn. 2013,
More information